Analytical Data
-
基因名
HLA-A*02:01&B2M&HPV16 E6(KLPQLCTEL) Tetramer
- Application
-
别名
rHuHLA-A*0201 HPV16 E6 complex Protein
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A0A140T913 (G25-T305)&P61769
-
表达区间
A0A140T913 (G25-T305)&P61769 (I21-M119)&KLPQLCTEL
-
分子量
260-265 kDa under Non reducing (N)
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/HPV16 E6 (KLPQLCTEL) tetramer recombinant protein is pivotal in understanding immune responses against human papillomavirus (HPV) infection, which is closely associated with the development of cervical cancer. The HLA-A*02:01 allele is one of the most prevalent human leukocyte antigen molecules, playing a crucial role in presenting viral peptides to CD8+ T cells, thereby initiating a cytotoxic T cell response. The E6 protein of HPV16 is a key oncogenic factor that interferes with host cellular mechanisms, and the specific peptide KLPQLCTEL is recognized by T cells in HLA-A*02:01 restricted pathways. The development of tetrameric complexes that consist of HLA-A*02:01, β2-microglobulin (B2M), and the HPV16 E6 peptide allows for the direct visualization and quantification of HPV E6-specific T cells in peripheral blood. This approach enhances our understanding of the immune landscape in HPV-associated malignancies and aids in the evaluation of immunotherapeutic strategies. By leveraging tetramer technology, researchers can analyze T cell responses, monitor vaccine efficacy, and explore the potential for personalized immunotherapies against HPV-induced cancers. This research ultimately contributes to the advancement of effective prevention and treatment strategies for HPV-related diseases, aiming to reduce cervical cancer incidence globally.
